Clovis Oncology (CLVS) Downgraded by BidaskClub to “Sell”

BidaskClub downgraded shares of Clovis Oncology (NASDAQ:CLVS) from a hold rating to a sell rating in a research note issued to investors on Thursday.

Several other equities analysts have also issued reports on CLVS. Oppenheimer reissued a hold rating on shares of Clovis Oncology in a research note on Wednesday, December 20th. ValuEngine raised Clovis Oncology from a sell rating to a hold rating in a research note on Friday, December 29th. JPMorgan Chase reissued a buy rating on shares of Clovis Oncology in a research note on Thursday, January 11th. Zacks Investment Research lowered Clovis Oncology from a hold rating to a sell rating in a research note on Tuesday, January 16th. Finally, Credit Suisse Group set a $86.00 price target on Clovis Oncology and gave the company a buy rating in a research note on Thursday, January 18th. They noted that the move was a valuation call. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have issued a buy rating to the company’s stock. Clovis Oncology has an average rating of Buy and an average price target of $87.60.

How to Become a New Pot Stock Millionaire

Shares of CLVS stock opened at $50.17 on Thursday. Clovis Oncology has a one year low of $45.42 and a one year high of $99.45. The company has a current ratio of 7.69, a quick ratio of 7.35 and a debt-to-equity ratio of 0.77.



Clovis Oncology (NASDAQ:CLVS) last announced its earnings results on Monday, February 26th. The biopharmaceutical company reported ($1.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($1.29) by $0.25. Clovis Oncology had a negative return on equity of 81.34% and a negative net margin of 624.02%. The business had revenue of $17.04 million for the quarter, compared to analysts’ expectations of $19.42 million. During the same period in the prior year, the business posted ($1.83) earnings per share. The firm’s revenue was up 21746.2% on a year-over-year basis. equities research analysts predict that Clovis Oncology will post -4.67 earnings per share for the current year.

In other news, Director Thorlef Spickschen sold 4,500 shares of the company’s stock in a transaction that occurred on Thursday, March 8th. The stock was sold at an average price of $61.47, for a total transaction of $276,615.00. Following the transaction, the director now directly owns 12,118 shares of the company’s stock, valued at $744,893.46. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the company’s stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $54.09, for a total value of $162,270.00. Following the transaction, the insider now directly owns 180,571 shares in the company, valued at $9,767,085.39. The disclosure for this sale can be found here. Insiders have sold 16,500 shares of company stock worth $978,975 over the last ninety days. 12.50% of the stock is owned by insiders.

Several large investors have recently modified their holdings of CLVS. HealthCor Management L.P. raised its position in Clovis Oncology by 50.4% in the 4th quarter. HealthCor Management L.P. now owns 973,840 shares of the biopharmaceutical company’s stock valued at $66,221,000 after buying an additional 326,420 shares during the last quarter. Redmile Group LLC raised its position in Clovis Oncology by 32.5% in the 4th quarter. Redmile Group LLC now owns 1,320,027 shares of the biopharmaceutical company’s stock valued at $89,762,000 after buying an additional 323,417 shares during the last quarter. Franklin Resources Inc. raised its position in Clovis Oncology by 13.8% in the 4th quarter. Franklin Resources Inc. now owns 2,634,401 shares of the biopharmaceutical company’s stock valued at $179,138,000 after buying an additional 318,931 shares during the last quarter. Millennium Management LLC purchased a new stake in Clovis Oncology in the 4th quarter valued at $17,652,000. Finally, UBS Asset Management Americas Inc. raised its position in Clovis Oncology by 47.7% in the 4th quarter. UBS Asset Management Americas Inc. now owns 552,082 shares of the biopharmaceutical company’s stock valued at $37,542,000 after buying an additional 178,337 shares during the last quarter. 98.19% of the stock is currently owned by institutional investors.

ILLEGAL ACTIVITY WARNING: “Clovis Oncology (CLVS) Downgraded by BidaskClub to “Sell”” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are viewing this piece on another publication, it was stolen and reposted in violation of U.S. and international copyright and trademark laws. The original version of this piece can be viewed at https://stocknewstimes.com/2018/04/23/clovis-oncology-clvs-downgraded-by-bidaskclub-to-sell.html.

Clovis Oncology Company Profile

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply